Use of intravenous prostanoids, sildenafil and bosentan for management of digital ulcer disease in systemic sclerosis in south-west England and Wales prior to and after 2015
| Iloprost | Sildenafil | Bosentan | Iloprost | Sildenafil | Bosentan | Iloprost | Sildenafil | Bosentan | |
|---|---|---|---|---|---|---|---|---|---|
| All regions, n=113 | South-west England, n=85 | Wales, n=28 | |||||||
| SSc-DU management prior to 2015, n (%) | 66 (58.4) | 19 (16.8) | 6 (5.3) | 41(48.2) p=0.0001, vs Wales | 10 (11.8) p=0.019, vs Wales | 5 (5.9) | 25 (89.3) | 9 (32.1) | 1 (3.6) |
| All regions, n=128 | South-west England, n=92 | Wales, n=36 | |||||||
| SSc-DU management at 2017, n (%) | 79 (61.7) | 33 (25.8) | 9 (7.0) | 49 (53.3) | 22(23.9) p=0.049, vs prior to 2015 | 8 (8.7) | 30 (83.3) | 11 (30.6) | 1 (2.8) |
Iloprost therapy was used for either Raynaud's phenomenon or digital ulcer disease; p values were calculated using Fisher's exact test. SSc-DU = digital ulcer disease in systemic sclerosis.